About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Dynamic Focusing Evaluation for Prostate Cancer Treatment

Dynamic Focusing Evaluation for Prostate Cancer Treatment

NCT03632980·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

EDAP TMS S.A.

Age

70–any

Sex

MALE

Healthy volunteers

Not accepted

You may be eligible if

Age \> 70 years
T1 or T2
PSA \< 15 ng/mL
12 randomized biopsies
Gleason score ≤ 3+4
Normal anal and rectal anatomy
American Society of Anesthesiologists risk (ASA) 1 or 2
Age \> 50 years
T1 or T2
Biochemical recurrence after radiotherapy (Phoenix definition: nadir+2ng/ml)
12 randomized biopsies
Normal anal and rectal anatomy
ASA 1 or 2

You may not be if

T3 patients
American Society of Anesthesiologists risk (ASA) 3
Metastatic disease (Bone scan…)
Previous prostate cancer therapy
Distance between rectal mucosa and prostatic capsule of more than 8 mm thickness
Prostate volume over 50cc
Previous bladder cancer
contraindication to MRI
previous rectal or urinary fistulae
T3 patients
ASA 3
Metastatic disease (Bone scan…)
Distance between rectal mucosa and prostatic capsule of more than 8 mm thickness
Prostate volume over 50cc
Previous bladder cancer
contraindication to MRI
previous rectal or urinary fistulae

The record

StatusUnknown

PhaseNo phase

Taking part180

StartedJun 2011

UpdatedAug 16, 2018

Conditions

Cancer of Prostate

Where1

Edouard Herriot Hospital
Lyon, France